Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma

Daisuke Watanabe; Akemi Yamashita; Tadaaki Minowa; Kunihisa Miura; Akio Mizushima

doi:10.1016/j.eucr.2019.100933

Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma

Urol Case Rep. 2019 Jun 4:26:100933. doi: 10.1016/j.eucr.2019.100933. eCollection 2019 Sep.

Authors

Daisuke Watanabe^{1

2}, Akemi Yamashita², Tadaaki Minowa², Kunihisa Miura³, Akio Mizushima¹

Affiliations

¹ Department of Palliative Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
² Department of Urology, Koto Hospital, Tokyo, Japan.
³ Department of Anesthesiology and Pain Medicine, Koto Hospital, Tokyo, Japan.

Abstract

There are currently several options for tyrosine kinase inhibitor as a systemic therapy for metastatic renal cell carcinoma (mRCC). The successful control of adverse events caused by such drugs, along with eliciting long-term maximum effect, are the major issues with respect to the treatment strategy for mRCC. We herein report the clinical course of mRCC, in which erythema multiforme major was observed on the 13th day of the first course of sunitinib, but the symptoms improved after the immediate withdrawal of sunitinib, as well as the administration of topical steroids and oral antihistamines alone.

Keywords: Erythema multiforme major; Renal cell carcinoma; Sunitinib.

Publication types

Case Reports